Kolmar BioTech. Inc. 215380

KRX · South Korea · Process Industries

KRW 2,320.00+35.00 (+1.53%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Kolmar BioTech. Inc. 215380

KRX · South Korea · Process Industries

KRW 2,320.00+35.00 (+1.53%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-5.31% · 6MFull-screen chart

Open KRW 2,285.00High KRW 2,365.00Low KRW 2,275.00Close KRW 2,320.00Volume 37.65K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 2,285.00
Day range: KRW 2,275.00 – KRW 2,365.00
52-week range: KRW 1,681.00 – KRW 4,535.00
Volume: 37.65K
Market cap: KRW 38.09B
Avg. volume (1Y): 556.79K

Performance

1 week

+1.31%

1 month

+8.41%

3 months

-8.84%

6 months

-7.57%

Year to date

+30.34%

1 year

+34.10%

Total return, dividends included.

Company profile

Sector: Process Industries
Industry: Agricultural Commodities/Milling
Country: South Korea
Exchange: KRX
Shares outstanding: 16.67M
Employees: 127
ISIN: KR7215380007
Beta: 0.31

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJan 06, 2026

Xellar and WOOJUNG BIO Announce Multi-Year Strategic Partnership to Advance AI-Enabled Hybrid Human Organ-on-a-Chip (OoC)-Animal Preclinical Platforms

Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, today announced that it has entered into a multi-year strategic collaboration agreement with WOOJUNG BIO Co., Ltd. ("WOOJUNG BIO"; KOSDAQ: 215380), a Korea-listed biotechnology company with strong capabilities in translational research and life sciences services.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.